Active substance |
upadacitinib |
Holder | AbbVie Belgium sa/nv |
Status | closed |
Indication | patients (adults and adolescents ≥ 12 years old) with severe atopic dermatitis who have no other suitable treatment option and are not eligible to participate in a clinical study |
Public documents | Approbation |
Approbation amendment | |
Information for the patient | |
Informed consent | |
Last update | 04/09/2023 |